In early May 2024, Celltrion reported that two of its biosimilar products, infliximab and trastuzumab, won the public tender in Peru, further expanding their prescription availability in Peru and solidifying their position in the broader Latin American pharmaceutical market.
Celltrion wins Peruvian public tenders for biosimilar infliximab and trastuzumab
Home/Pharma News
|
Posted 28/05/2024
0
Post your comment
![Turkey 2016 COVER V16E31DG Turkey 2016 COVER V16E31DG](/var/gabi/storage/images/media/images/turkey-2016-cover-v16e31dg/51945-1-eng-GB/Turkey-2016-COVER-V16E31DG_large.jpg)
The company’s biosimilar for autoimmune disease treatment Remsima (infliximab, which references Janssen’s Remicade) won a Peruvian Workers' Insurance System (EsSalud) tender. The company notes that the tender is the largest of its kind accounting for 81% of the total infliximab volume in Peru.
Celltrion intends to supply Remsima for one year beginning in May 2024 and anticipates that the product will have an 86% market share in Peru.
Additionally, Celltrion won a tender from the Peruvian Ministry of Health (Centro Nacional de Abastecimiento de Recursos Estratégicos en Salud, CENARES) for its trastuzumab biosimilar, Herzuma (which references Genentech’s Herceptin), used to treat breast and gastric cancer. The tender represents about half of the trastuzumab market in Peru. Celltrion will provide a one-year supply of Herzuma starting in July 2024.
Earlier in 2024, Celltrion won public tenders in Peru for its rituximab biosimilar, Truxima, as well as its adalimumab biosimilar, Yuflyma.
The Korean company, through its local subsidiaries, has focused on building a network of contacts with healthcare providers, regulators, and government officials in Peru. Based on these activities, Celltrion has optimized and tailored its strategy for each tender, resulting in the winning of all four of its products.
Celltrion intends to keep up introducing more products and continue its expansion in Peru. They plan to launch in May 2024 Vegzelma, a bevacizumab biosimilar for treating colorectal and lung cancer.
The first biosimilar to receive approval in Peru was Celltrion’s monoclonal antibody Flixceli (infliximab) in 2016 [1]. That year, the Ministry of Health, MINSA, released a national biosimilar regulatory framework in 2016 in an effort to boost the domestic biologicals market [2].
Related articles
Regulatory landscape for biosimilars in Latin America
Peru issues decree for the registration of medicines and biological products
LATIN AMERICAN FORUM View the latest headline article: Guía de la FDA sobre etiquetado promocional y publicidad de productos biológicos, biosimilares e intercambiables Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.
FORO LATINOAMERICANO Ver el último artículo de cabecera: Guía de la FDA sobre etiquetado promocional y publicidad de productos biológicos, biosimilares e intercambiables !Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. |
References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Peru [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 May 28]. Available from: www.gabionline.net/biosimilars/general/biosimilars-approved-in-peru
2. GaBI Online - Generics and Biosimilars Initiative. The biosimilars market in Latin America: a summary [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 May 28]. Available from: www.gabionline.net/biosimilars/research/The-biosimilars-market-in-Latin-America-a-summary
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2024 Pro Pharma Communications International. All Rights Reserved.
Policies & Legislation
China’s NMPA expands global ties with Netherlands and Indonesia
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Coherus sells adalimumab biosimilar Yusimry to HKF for US$40 million amid oncology focus
Biocon and Biomm forge alliance to bring semaglutide diabetes treatment to Brazil
Klinge–MS Pharma and Teva–mAbxience biosimilars licence agreements
Bio-Thera and SteinCares sign agreement to market two biosimilars in LATAM
Coherus sells adalimumab biosimilar Yusimry to HKF for US$40 million amid oncology focus
![Application V15a16 Application V15a16](/var/gabi/storage/images/media/images/application-v15a16/25577-1-eng-GB/Application-V15a16_large.jpg)
Home/Pharma News Posted 16/07/2024
Biocon and Biomm forge alliance to bring semaglutide diabetes treatment to Brazil
![Diabetes V14K06 Diabetes V14K06](/var/gabi/storage/images/media/images/diabetes-v14k06/24897-1-eng-GB/Diabetes-V14K06_large.jpg)
Home/Pharma News Posted 12/06/2024
Klinge–MS Pharma and Teva–mAbxience biosimilars licence agreements
![Shaking hands V13D29 Shaking hands V13D29](/var/gabi/storage/images/media/images/shaking-hands-v13d294/22672-1-eng-GB/Shaking-hands-V13D29_large.jpg)
Home/Pharma News Posted 05/06/2024
Bio-Thera and SteinCares sign agreement to market two biosimilars in LATAM
![02 AA010638 02 AA010638](/var/gabi/storage/images/media/images/02-aa010638/21726-1-eng-GB/02-AA010638_large.jpg)
Home/Pharma News Posted 14/05/2024
The best selling biotechnology drugs of 2008: the next biosimilars targets
![picture09 picture09](/var/gabi/storage/images/media/images/picture09/2207-2-eng-GB/picture09_large.jpg)
Post your comment